Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Buy" by Brokerages

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has earned a consensus rating of "Buy" from the six brokerages that are currently covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $19.50.

A number of research firms recently commented on ZVRA. Cantor Fitzgerald restated an "overweight" rating on shares of Zevra Therapeutics in a report on Monday, April 1st. HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday. William Blair reissued an "outperform" rating on shares of Zevra Therapeutics in a research report on Tuesday, March 12th. Finally, Maxim Group increased their price objective on Zevra Therapeutics from $12.00 to $18.00 and gave the company a "buy" rating in a research report on Tuesday.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in Zevra Therapeutics during the third quarter worth $71,000. City State Bank acquired a new position in Zevra Therapeutics during the third quarter worth $69,000. Measured Wealth Private Client Group LLC acquired a new position in Zevra Therapeutics during the third quarter worth $48,000. Commonwealth Equity Services LLC acquired a new position in Zevra Therapeutics during the third quarter worth $52,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new position in Zevra Therapeutics during the third quarter worth $126,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Price Performance

NASDAQ ZVRA traded down $0.09 on Friday, reaching $4.82. The company's stock had a trading volume of 192,240 shares, compared to its average volume of 258,699. Zevra Therapeutics has a twelve month low of $3.89 and a twelve month high of $7.28. The company has a debt-to-equity ratio of 0.65, a quick ratio of 6.31 and a current ratio of 6.31. The stock has a market cap of $209.33 million, a PE ratio of -3.74 and a beta of 1.81. The firm's 50 day moving average is $6.09 and its two-hundred day moving average is $5.37.

About Zevra Therapeutics

Zevra Therapeutics, Inc, a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.